US online marketplace eBay has agreed to acquire fashion resale platform Depop from Etsy in a $1.2bn cash deal. The transaction is expected to close in the second quarter of 2026. Depop will continue to operate under its existing name, brand identity, platform and culture after the acquisition. Depop operates as a mobile-first consumer-to-consumer (C2C) fashion marketplace. It generated approximately $1bn in annual gross merchandise sales (GMS) in 2025, with nearly 60% year-on-year growth in the US. ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best immunotherapy stocks to buy according to hedge funds. AstraZeneca PLC (NASDAQ:AZN) received an update from Deutsche Bank on February 16, with the firm reiterating a Sell rating on the stock and setting a price target of £115. AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation In a separate development, AstraZeneca PLC (NASDAQ:AZN) announced on February 13 the full results from the positive Phase III KALOS and LOGOS trials, showing ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best immunotherapy stocks to buy according to hedge funds. Gilead Sciences, Inc. (NASDAQ:GILD) announced its fiscal Q4 and full year 2025 results on February 10, reporting a strong year marked by the continued growth of Biktarvy and Descovy, along with the successful launch of Yeztugo, the world’s first twice-yearly HIV prevention therapy in the country. Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs Gilead Sciences, Inc. ( ...

Amgen Inc. (NASDAQ:AMGN) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Amgen Inc. (NASDAQ:AMGN) was downgraded to Hold from Buy by Freedom Capital, with the firm adjusting the price target on the stock to $375 from $360. It told investors in a research note that while it views the company’s fiscal Q4 report as “strong”, the shares are at fair value and loss of exclusivity headwinds remain for Amgen Inc. (NASDAQ:AMGN). RBC Lifts Amgen (AMGN) Target After Strong Q4 ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best immunotherapy stocks to buy according to hedge funds. Bristol-Myers Squibb Company (NYSE:BMY) announced on February 12 plans to become an inaugural partner to Life Science Cares in support of its national campaign in fighting food insecurity. Management reported that the Food is Health: Nourishing Communities, Advancing Health initiative, led by Life Science Cares, aims to invest $30 million and mobilize 30,000 volunteer hours by 2030 to deliver a ...

Skyrocketing demand for memory chips has made Micron Technology (NASDAQ: MU) one of the market's top performers in recent months. An investment of $10,000 in shares of Micron made just two years ago would now be worth nearly $52,000. It is easy to see why Micron stock has become a multibagger so quickly. Due to the massive buildout of artificial intelligence (AI) data centers, demand for the types of memory it manufactures is well exceeding supply, which has led to a sharp jump in prices. The good news fo ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on February 10, setting a price target of $745.00. Regeneron (REGN) Draws Higher Target From TD Cowen The same day, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) highlighted its expanding immunology portfolio and pipeline, announcing that 36 abstracts across its immunology and inflammation portfolio and ...

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansio ...

Merck & Co., Inc. (NYSE:MRK) is one of the best immunotherapy stocks to buy according to hedge funds. On February 13, Merck & Co., Inc. (NYSE:MRK) was upgraded to Buy from Hold by Deutsche Bank, with the firm raising the price target to $150 from $115 and telling investors that it believes the market is undervaluing the company because of Keytruda’s looming patent cliff. The firm’s analysis demonstrates a “clear path” for the company to navigate the transition effectively, adding that it believes Merck & C ...

Rackspace Technology (RXT) shares more than tripled on Wednesday after the Nasdaq-listed firm announced a new strategic partnership with Palantir Technologies (PLTR). This massive surge of retail interest pushed RXT’s relative strength index (14-day) into the late 70s, indicating extremely overbought conditions that often precede a sharp correction. Despite its meteoric run, however, Rackspace stock remains down more than 50% versus its 52-week high. More News from Barchart www.barchart.com Does Palan ...